Giampaolo Bianchini· @BianchiniGP · X·· 1 day agoScore70
Body
🔥 Abema + fulvestrant after 1L CDK4/6i/AI improves PFS, PFS2 & time to chemo; numerical ↑OS
👉 CDK targeting remains valid post-CDK4/6i, but NOT a class effect!
✅ Abema (postMONARCH, EMBER-3), atirmociclib (FourLight-1), ribo (MAINTAIN)
⛔ Palbo (PACE, PALMIRA)
#ESMO26
50 views · 1 like · 0 reposts · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: Giampaolo Bianchini · x.com